WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Thank you for another great WorkBoat Show! We hope to see everyone back in New Orleans December 2–4, 2026. Save the date!

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CorMedix Inc. - Common Stock (NQ:CRMD)

12.15 +0.17 (+1.42%)
Streaming Delayed Price Updated: 11:46 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CorMedix Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why CorMedix Could be the Biopharma Name to Watch Early in 2026 ↗
Via MarketBeat
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
Via MarketBeat
News headline image
Why Is CorMedix Stock Rising Today? ↗
CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study. 
Via Stocktwits
News headline image
CorMedix Inc (NASDAQ:CRMD) Shows Explosive Growth Metrics in "Little Book" Screen ↗
CorMedix (CRMD) shows explosive sales & earnings growth, strong momentum, and a surprisingly low valuation, making it a top growth stock candidate. 
Via Chartmill
News headline image
Talphera (TLPH) Q3 2025 Earnings Call Transcript ↗
Talphera (TLPH) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
CorMedix Stock Breaks Out To 2-Month High: Analysts Reset Price Targets After Blowout Q3 And Surging DefenCath Demand ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast? ↗
Via Stocktwits
News headline image
Analyst Expectations For Cormedix's Future ↗
 
Via Benzinga
News headline image
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations ↗
CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress. 
Via Benzinga
News headline image
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance ↗
The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million. 
Via Stocktwits
Topics Earnings
News headline image
CorMedix Inc. (NASDAQ:CRMD) Q3 2025 Earnings: Revenue Beat Offsets EPS Miss ↗
CorMedix Inc. (CRMD) Q3 2025 earnings show a revenue beat of $104.3M, but an EPS miss. The stock rose in pre-market trading on strong sales growth. 
Via Chartmill
News headline image
CorMedix Inc (NASDAQ:CRMD) Fulfills Key Growth Stock Criteria from The Little Book ↗
CorMedix (CRMD) excels in a proven growth stock strategy, showing massive sales growth, strong earnings momentum, and solid profitability metrics. 
Via Chartmill
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ ↗
Via Stocktwits
News headline image
Top Stocks With Earnings This Week: Plug, Oklo, Circle And More ↗
Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle. 
Via Benzinga
News headline image
Beyond The Numbers: 4 Analysts Discuss Cormedix Stock ↗
 
Via Benzinga
News headline image
CorMedix Inc (NASDAQ:CRMD) Fits a Proven Growth Strategy with Strong Fundamentals ↗
CorMedix Inc. fits a proven growth investing strategy with explosive revenue growth, soaring profits, and strong analyst revisions, signaling high potential. 
Via Chartmill
News headline image
CorMedix Inc (NASDAQ:CRMD) Identified as a Top Growth Stock Candidate ↗
CorMedix Inc (CRMD) identified as a top growth stock using Louis Navellier's strategy, showing explosive revenue growth, soaring earnings estimates, and strong profitability. 
Via Chartmill
News headline image
CorMedix Inc (NASDAQ:CRMD) Embodies a Proven Growth Investing Strategy ↗
CorMedix (CRMD) excels in Louis Navellier's growth strategy with massive revenue growth, soaring earnings, and high ROE, making it a top stock to watch. 
Via Chartmill
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
CORMEDIX INC (NASDAQ:CRMD) – A High-Growth Stock Aligned with Louis Navellier’s Investment Strategy ↗
Discover how CORMEDIX INC (CRMD) aligns with Louis Navellier’s growth investing strategy, showcasing strong earnings momentum, rapid revenue growth, and high ROE for potential stock gains. 
Via Chartmill
News headline image
Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter ↗
Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise. 
Via Benzinga
Topics Stocks
News headline image
Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes ↗
Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles. 
Via Benzinga
Topics Bankruptcy
News headline image
CorMedix Inc (NASDAQ:CRMD) Reports Strong Q2 2025 Earnings, Beats Estimates and Announces Strategic Acquisition ↗
CorMedix Inc (CRMD) reported strong Q2 2025 earnings, beating revenue and EPS estimates, with shares rising in pre-market trading. The company also announced the acquisition of Melinta Therapeutics. 
Via Chartmill
Topics Earnings
News headline image
CorMedix Analyst Says Investors Could Be Further Rewarded ↗
CorMedix boosts Q2 sales forecast as a major dialysis client accelerates DefenCath use, prompting positive analyst coverage and growth outlook. 
Via Benzinga
News headline image
This CorMedix Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
CorMedix Stock Tumbles After $85M Stock Sale; But Retail Sees Bargain In DefenCath Bet ↗
The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2025 Diversified Communications. All rights reserved.